Related Experiment Video

Updated: May 29, 2026

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
06:04

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Published on: February 24, 2023

Life-threatening pneumonia caused by macrolide-resistant Mycoplasma pneumoniae

Yu-Chia Hsieh, Kuo-Chien Tsao, Chung-Guei Huang

    The Pediatric Infectious Disease Journal
    |September 24, 2011
    PubMed

    Insights

    Macrolide-resistant Mycoplasma pneumoniae caused severe pneumonia in two siblings. One required extracorporeal membrane oxygenation, highlighting the need for better treatment strategies for this resistant infection.

    Area of Science:

    • Pulmonology
    • Infectious Diseases
    • Microbiology

    Background:

    • Macrolide antibiotics are a common treatment for Mycoplasma pneumoniae infections.
    • Increasing macrolide resistance in M. pneumoniae poses a therapeutic challenge.

    Observation:

    • Two siblings presented with pneumonia confirmed to be caused by macrolide-resistant Mycoplasma pneumoniae.
    • Diagnostic methods included polymerase chain reaction and serology.
    • One sibling experienced severe illness, developing adult respiratory distress syndrome.

    Findings:

    • The resistant M. pneumoniae strain led to severe pneumonia in both siblings.
    • Extracorporeal membrane oxygenation (ECMO) was necessary for one patient, indicating disease severity.
    • Standard macrolide treatment was likely ineffective due to resistance.

    Implications:

    • This case underscores the clinical significance of macrolide-resistant M. pneumoniae.
    • Further research is crucial to establish optimal treatment protocols for severe cases.
    • Physicians should consider antibiotic resistance when treating M. pneumoniae pneumonia, especially in severe or refractory cases.

    Related Concept Videos

    Atypical Pneumonia01:14

    Atypical Pneumonia

    Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
    Pneumonia I: Introduction01:29

    Pneumonia I: Introduction

    Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
    Pneumonia I: Introduction01:30

    Pneumonia I: Introduction

    Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
    Risk Factors
    Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
    Mechanism of Antibiotic Resistance in MRSA01:25

    Mechanism of Antibiotic Resistance in MRSA

    Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
    Pneumonia III: Complications and Assessment01:30

    Pneumonia III: Complications and Assessment

    Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
    Pneumonia II: Pathophysiology01:29

    Pneumonia II: Pathophysiology

    The pathophysiology of pneumonia involves the following steps: